Preemptive therapy for the prevention of cytomegalovirus disease following heart transplantation directed by PP65 antigenemia

Transplant Proc. 2003 Mar;35(2):732-4. doi: 10.1016/s0041-1345(03)00068-x.
No abstract available

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Cytomegalovirus Infections / diagnosis
  • Cytomegalovirus Infections / prevention & control*
  • Female
  • Follow-Up Studies
  • Ganciclovir / therapeutic use*
  • Heart Transplantation / adverse effects*
  • Humans
  • Male
  • Patient Selection
  • Phosphoproteins / blood*
  • Postoperative Complications / prevention & control
  • Postoperative Complications / virology
  • Prospective Studies
  • Time Factors
  • Viral Matrix Proteins / blood*

Substances

  • Antiviral Agents
  • Phosphoproteins
  • Viral Matrix Proteins
  • cytomegalovirus matrix protein 65kDa
  • Ganciclovir